Gene doping

Handbook of Experimental Pharmacology

Volumn 195, Issue , 2010, Pages 485-512

  Azzazy, Hassan M E ^a  

^a The American University in Cairo   (Egypt)

Author keywords

Erythropoietin; Gene delivery; Gene doping; Hypoxia inducible factors; Insulin like growth factor 1; Myostatin

Indexed keywords

ATHLETE; COMPETITION; DOPING; GENE TARGETING; GENE THERAPY; GENETIC ENGINEERING; HUMAN; MUSCLE DEVELOPMENT; NONHUMAN; OXYGEN TRANSPORT; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SPORT; TRANSGENIC ORGANISM; TRANSGENICS; BIOSYNTHESIS; GENE TRANSFER; GENE VECTOR; GENETICS; METHODOLOGY; VIRUS;

MUSCLE PROTEIN;

DOPING IN SPORTS; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; MUSCLE PROTEINS; VIRUSES;

EID: 77449119892     PISSN: 01712004     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-79088-4_20     Document Type: Review

References (81)

1. Amabile PG, Waugh JM, Lewis TN et al (2001) High-efficiency endovascular gene delivery via therapeutic ultrasound. J Am Coll Cardiol 37:1975-1980
2. Azzazy HM, Mansour MM (2007) Rogue athletes and recombinant DNA technology: challenges for doping control. Analyst 132:951-957
3. Azzazy HM, Mansour MM, Christenson RH (2005) Doping in the recombinant era: strategies and counterstrategies. Clin Biochem 38:959-965
4. Baoutina A, Alexander IE, Rasko JE et al (2007) Potential use of gene transfer in athletic performance enhancement. Mol Ther 15:1751-1766
5. Baoutina A, Alexander IE, Rasko JE et al (2008) Developing strategies for detection of gene doping. J Gene Med 10:3-20
6. Bidlingmaier M, Wu Z, Strasburger CJ (2003) Problems with GH doping in sports. J Endocrinol Invest 26:924-931
7. BRENDA: The Comprehensive Enzyme Information System. http://www.brenda- enzymes.org
8. Caldini A, Moneti G, Fanelli A et al (2003) Epoetin alpha, epoetin beta and darbepoetin alfa: two-dimensional gel electrophoresis isoforms characterization and mass spectrometry analysis. Proteomics 3:937-941
9. Cartier R, Reszka R (2002) Utilization of synthetic peptides containing nuclear localization signals for nonviral gene transfer systems. Gene Ther 9:157-167
10. Chaudhuri JD (2005) Genes arrayed out for you: the amazing world of microarrays. Med Sci Monit 11:RA52-RA62
11. Chenuaud P, Larcher T, Rabinowitz JE et al (2004) Autoimmune anemia in macaques following erythropoietin gene therapy. Blood 103:3303-3304
12. Chung L, Clifford D, Buckley M et al (2006) Novel biomarkers of human growth hormone action from serum proteomic profiling using protein chip mass spectrometry. J Clin Endocrinol Metab 91:671-677
13. Comerota AJ, Throm RC, Miller KA et al (2002) Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial. J Vasc Surg 35:930-936
14. DeFrancesco L (2004) The faking of champions. Nat Biotechnol 22:1069-1071
15. Diamanti-Kandarakis E, Konstantinopoulos PA, Papailiou J et al (2005) Erythropoietin abuse and erythropoietin gene doping: detection strategies in the genomic era. Sports Med 35:831-840
16. Díez S, Tros de Ilarduya C (2006) Versatility of biodegradable poly(D, L-lactic-co-glycolic acid) microspheres for plasmid DNA delivery. Eur J Pharm Biopharm 63:188-197
17. Favre D, Provost N, Blouin V et al (2001) Immediate and long-term safety of recombinant adenoassociated virus injection into the nonhuman primate muscle. Mol Ther 4:559-566
18. Fink D, Mata M, Glorioso JC (2003) Cell and gene therapy in the treatment of pain. Adv Drug Deliv Rev 55:1055-1064
19. Furalyov VA, Kravchenko IV, Khotchenkov VP et al (2008) siRNAs targeting mouse myostatin. Biochemistry (Mosc) 73:342-345
20. Gaffney GR, Parisotto R (2007) Gene doping: a review of performance-enhancing genetics. Pediatr Clin N Am 54:807-822
21. Gao G, Lu Y, Calcedo R et al (2006) Biology of AAV serotype vectors in liver-directed gene transfer to nonhuman primates. Mol Ther 13:77-87
22. Grimaldi PA (2005) Regulatory role of peroxisome proliferator-activated receptor delta (PPAR delta) in muscle metabolism. A new target for metabolic syndrome treatment? Biochimie 87:5-8
23. Hackett PB, Ekker SC, Largaespada DA et al (2005) Sleeping beauty transposon-mediated gene therapy for prolonged expression. Adv Genet 54:189-232
24. Haisma HJ, de Hon O (2006) Gene doping. Int J Sports Med 27:257-266
25. Hakimi P, Yang J, Casadesus G et al (2007) Overexpression of the cytosolic form of phosphoenolpyruvate carboxykinase (GTP) in skeletal muscle repatterns energy metabolism in the mouse. J Biol Chem 282:32844-32855
26. Hautala AJ, Leon AS, Skinner JS et al (2007) Peroxisome proliferator-activated receptor-delta polymorphisms are associated with physical performance and plasma lipids: the HERITAGE family study. Am J Physiol Heart Circ Physiol 292:H2498-H2505
27. Hernandez YJ, Wang J, Kearns WG et al (1999) Latent adeno-associated virus infection elicits humoral but not cell-mediated immune responses in a nonhuman primate model. J Virol 73:8549-8558
28. Hruskovicová H, Dzurenková D, Selingerová M et al (2006) The angiotensin converting enzyme I/D polymorphism in long distance runners. J Sports Med Phys Fitness 46:509-513
29. Inazawa T, Tanabe T, Yamada H et al (2001) Glucocorticoid-regulated expression of exogenous human growth hormone gene in rats. Mol Ther 4:267-272
30. Issaq HJ, Veenstra TD, Conrads TP et al (2002) The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem Biophys Res Commun 292:587-592
31. Jager L, Ehrhardt A (2007) Emerging adenoviral vectors for stable correction of genetic disorders. Curr Gene Ther 7:272-283
32. Joos L, Eryuksel E, Brutsche MH (2003) Functional genomics and gene microarrays - the use in research and clinical medicine. Swiss Med Wkly 133:31-38
33. Judge AD, Sood V, Shaw JR et al (2005) Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 23:457-462
34. Kaiser I (2003) Seeking the cause of induced leukemia in X-SCID. Science 24:495
35. Khan AS, Brown PA, Draghia-Akli R (2005) Plasmid-based growth hormone-releasing hormone supplementation and its applications. Curr Opin Mol Ther 7:306-316
36. Koshkina NV, Agoulnik IY, Melton SL et al (2003) Biodistribution and pharmacokinetics of aerosol and intravenously administered DNA-polyethyleneimine complexes: optimization of pulmonary delivery and retention. Mol Ther 8:249-254
37. Lasne F, Martin L, de Ceaurriz J et al (2004) "Genetic doping" with erythropoietin cDNA in primate muscle is detectable. Mol Ther 10:409-410
38. Lee S, Barton ER, Sweeney HL et al (2004) Viral expression of insulin-like growth factor-I enhances muscle hypertrophy in resistance-trained rats. J Appl Physiol 96:1097-1104
39. Lemkine GF, Demeneix BA (2001) Polyethylenimines for in vivo gene delivery. Curr Opin Mol Ther 3:178-182
40. Lippi G, Guidi GC (2004) Gene manipulation and improvement of athletic performances: new strategies in blood doping. Br J Sports Med 38:641
41. Lippi G, Franchini M, Salvagno GL et al (2006) Biochemistry, physiology, and complications of blood doping: facts and speculation. Crit Rev Clin Lab Sci 43:349-391
42. Liu D, Ren T, Gao X (2003) Cationic transfection lipids. Curr Med Chem 10:1307-1315
43. Macarthur DG, North KN (2005) Genes and human elite athletic performance. Hum Genet 116:331-339
44. Manno CS, Chew AJ, Hutchison S et al (2003) AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 101:2963-2972
45. Manno CS, Pierce GF, Arruda VR et al (2006) Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 12:342-347
46. McCrory P (2003) Super athletes or gene cheats? Br J Sports Med 37:192-193
47. Medarova Z, Pham W, Farrar C et al (2007) In vivo imaging of siRNA delivery and silencing in tumors. Nat Med 13:372-377
48. Morrissey DV, Lockridge JA, Shaw L et al (2005) Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 23:1002-1007
49. Nathwani AC, Davidoff AM, Hanawa H et al (2002) Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques. Blood 100:1662-1669
50. Niidome T, Huang L (2002) Gene therapy progress and prospects: nonviral vectors. Gene Ther 9:1647-1652
51. Oh YK, Kim JP, Hwang TS et al (2001) Nasal absorption and biodistribution of plasmid DNA: analternative route of DNA vaccine delivery. Vaccine 19:4519-4525
52. Parker SE, Borellini F, Wenk ML et al (1999) Plasmid DNA malaria vaccine: tissue distribution and safety studies in mice and rabbits. Hum Gene Ther 10:741-758
53. Pascual JA, Belalcazar V, de Bolos C et al (2004) Recombinant erythropoietin and analogues: a challenge for doping control. Ther Drug Monit 26:175-179
54. Quezada A, Larson J, French M et al (2004) Biodistribution and safety studies of hDel-1 plasmid-based gene therapy in mouse and rabbit models. J Pharm Pharmacol 56:177-185
55. Reilly SM, Lee CH (2008) PPAR delta as a therapeutic target in metabolic disease. FEBS Lett 582:26-31
56. Rip J, Nierman MC, Sierts JA et al (2005) Gene therapy for lipoprotein lipase deficiency: working toward clinical application. Hum Gene Ther 16:1276-1286
57. Rittner K, Benavente A, Bompard-Sorlet A et al (2002) New basic membrane-destabilizing peptides for plasmid-based gene delivery in vitro and in vivo. Mol Ther 5:104-114
58. Romero NB, Braun S, Benveniste O et al (2004) Phase I study of dystrophin plasmid-based gene therapy in Duchenne/Becker muscular dystrophy. Hum Gene Ther 15:1065-1076
59. Schertzer JD, Lynch GS (2006) Comparative evaluation of IGF-I gene transfer and IGF-I protein administration for enhancing skeletal muscle regeneration after injury. Gene Ther 13:1657-1664
60. Schuelke M, Wagner KR, Stolz LE et al (2004) Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med 350:2682-2688
61. Sebestyen MG, Hegge JO, Noble MA et al (2007) Progress toward a nonviral gene therapy protocol for the treatment of anemia. Hum Gene Ther 18:269-285
62. Shyu KG, Chang H, Wang BW et al (2003) Intramuscular vascular endothelial growth factor gene therapy in patients with chronic critical leg ischemia. Am J Med 114:85-92
63. Siess DC, Vedder CT, Merkens LS et al (2000) A human gene coding for a membrane-associated nucleic acid-binding protein. J Biol Chem 275:33655-33662
64. Somia N, Verma IM (2000) Gene therapy: trials and tribulations. Nat Rev Genet 1:91-99
65. Suda T, Gao X, Stolz DB et al (2007) Structural impact of hydrodynamic injection on mouse liver. Gene Ther 14:129-137
66. Sweeney HL (2004) Gene doping. Sci Am 291:62-69
67. Tentori L, Graziani G (2007) Doping with growth hormone/IGF-1, anabolic steroids or erythro-poietin: is there a cancer risk? Pharmacol Res 55:359-369
68. Thomas SM, Zeng Q, Dyer KF et al (2003) Tissue distribution of liposome-mediated epidermal growth factor receptor antisense gene therapy. Cancer Gene Ther 10:518-528
69. Tiong A, Freedman SB (2004) Gene therapy for cardiovascular disease: the potential of VEGF. Curr Opin Mol Ther 6:151-159
70. Unal M, Ozer Unal D (2004) Gene doping in sports. Sports 34:357-362
71. Voutetakis A, Bossis I, Kok MR et al (2005) Salivary glands as a potential gene transfer target for gene therapeutics of some monogenetic endocrine disorders. J Endocrinol 185:363-372
72. WADA (World Anti-Doping Agency); http://www.wada-ama.org, cited 25 Jan 2009
73. Wang YX, Zhang CL, Yu RT et al (2004) Regulation of muscle fiber type and running endurance by PPARdelta. PLoS Biol 2:e294
74. Whittemore LA, Song K, Li X et al (2003) Inhibition of myostatin in adult mice increases skeletal muscle mass and strength. Biochem Biophys Res Commun 300:965-971
75. Widera G, Austin M, Rabussay D et al (2000) Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol 164:4635-4640
76. Wilber RL (2002) Detection of DNA-recombinant human epoetin-alpha as a pharmacological ergogenic aid. Sports Med 32:125-142
77. Wolff JA, Budker V (2005) The mechanism of naked DNA uptake and expression. Adv Genet 54:3-20
78. Yew NS, Zhao H, Wu IH et al (2000) Reduced inflammatory response to plasmid DNA vectors by elimination and inhibition of immunostimulatory CpG motifs. Mol Ther 1:255-262
79. Yoshida S, Kashiwamura SI, Hosoya Y et al (2000) Direct immunization of malaria DNA vaccine into the liver by gene gun protects against lethal challenge of Plasmodium berghei sporozoite. Biochem Biophys Res Commun 271:107-115
80. Zhang JS, Liu F, Conwell CC et al (2006) Mechanistic studies of sequential injection of cationic liposome and plasmid DNA. Mol Ther 13:429-437
81. Zhou S, Murphy JE, Escobedo JA et al (1998) Adeno-associated virus-mediated delivery of erythropoietin leads to sustained elevation of hematocrit in nonhuman primates. Gene Ther 5:665-670